Key result
MicroRNAs emerge as key biomarkers and therapeutic targets across stroke diagnosis, prognosis, and treatment.
Stroke is a life-threatening disease that accounts for a considerable burden of mortality in both developing and developed world. Identification of specific biomarkers for stroke and its outcomes can greatly contribute to improved care of patients. MicroRNAs (miRNAs) are known as novel biomarkers that could be used as diagnostic, prognostic, and therapeutic biomarkers. Various studies have shown that miRNAs have key roles in the pathogenesis of stroke, and its complications and outcomes. In addition, there is evidence showing that mesenchaymal stromal cell-derived exosomes containing miRNAs can be used for monitoring and treatment of various diseases such as stroke. Here, we summarized various aspects of miRNA applications in different stages of stroke.
No takes yet. Share an insight, caveat, or question.
Mirzaei et al. (2017) conducted a review in Stroke. MicroRNAs (miRNAs) was evaluated. MicroRNAs serve as novel biomarkers with key roles in the pathogenesis, diagnosis, prognosis, and potential treatment of stroke, including via mesenchymal stromal cell-derived exosomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: